相关实验视频
Updated: Jul 27, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
976
普罗普拉诺洛能影响婴儿血瘤中的血小板指数吗?
Nilgun Eroglu1, Hilal Susam Sen1, Yeter Duzenli Kar1
1Departments of Pediatric Hematology and Oncology.
Journal of pediatric hematology/oncology
|June 6, 2023
概括
治疗婴儿血管瘤 (IH) 的普拉诺洛尔可能会改变血小板体积指数 (PVI). 研究人员在接受治疗的患者中观察到平均血小板体积 (MPV) 和血小板分布宽度 (PDW) 的显著变化,这表明PVI可以监测治疗反应.
科学领域:
- 儿科皮肤学 儿科皮肤学
- 血管生物学 血管生物学
- 血液学 血液学 血液学
背景情况:
- 婴儿血管瘤 (IH) 是一个常见的儿科血管瘤.
- 作为β阻塞剂的普罗巴诺洛尔是IH的第一线治疗方法,可降低血管内皮生长因子 (VEGF) 和血管生成.
- 血小板体积指数 (PVI),如平均血小板体积 (MPV) 和血小板分布宽度 (PDW),与VEGF水平有关.
研究的目的:
- 为了研究罗在患有婴儿血瘤的患者的PVI上的作用.
- 为了确定PVI是否可以作为IH中普拉诺洛尔治疗反应的标志物.
主要方法:
- 一项前性研究比较了22名IH患者接受了普罗兰诺洛尔治疗和25名未接受治疗的对照.
- 血小板计数,MPV,PDW和血小板位数在基线和治疗后1个月和2个月被测量.
- 进行了统计分析,以比较群体之间的PVI变化.
主要成果:
- 接受醇治疗的组在2个月内显示出MPV和PDW值的统计学显著变化.
- 在未接受治疗的对照组中,没有观察到MPV或PDW的显著变化.
- 在接受治疗的组中,PVI的这些变化可能与醇诱导的VEGF水平下降有关.
结论:
- 治疗婴儿血管瘤的普罗普拉诺洛尔与MPV和PDW的显著变化有关.
- PVI,特别是MPV和PDW,可以作为监测IH患者普拉诺洛尔治疗疗效的有用指标.
- 这一发现可以帮助临床医生评估治疗反应和疾病进展.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
569
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
569
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
895
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
895
Formation of the Platelet Plug
6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
223
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
223
Adrenergic Antagonists: ɑ and β-Receptor Blockers
524
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
524
Anticoagulant Drugs: Low-Molecular-Weight Heparins
767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767

